Valion Bio, Inc. (VBIO) Stock Price & Analysis
Valion Bio, Inc. (VBIO) — MoonshotScore 30/100 (Weak band), calculated Nov 18, 2026. Price $0.5399 (+9.96%), as of the Nov 19, 2026 trading session; market cap $1.16M.
Educational signal · not a buy or sell recommendation · How to read this
Valion Bio, Inc. · VBIO
Malachite Innovations, Inc., formerly Vitality Biopharma, focuses on developing cannabinoid pharmaceuticals for inflammatory disorders.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Valion Bio (VBIO)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a fragile balance sheet, stalling growth and an expensive valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Solid; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Shrinking; Momentum: Falling.
Earnings yield is the main valuation drag relative to sector peers.
- quarterly revenue $146,000 (Q3 FY2026, quarter ended Sep 30, 2025)
- EPS beat 8 of the last 8 reports
- Altman Z -4.49 · Piotroski F 2
Holding back: balance-sheet strain, a rich price, soft growth, weak price trend
Helping: business quality
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 28 | Weak | |
| 28 | Weak | |
| 28 | Weak | |
| 28 | Weak | |
| 30 | Weak | |
| 30 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.5399 | |
| Change on the day | +9.96% | |
| 52-week range | $0.4715 – $67.50 | |
| Market capitalisation | $1.16M | — |
| Shares traded on the day | 420.6K |
Price & events
Other perspectives
Council score for Valion Bio (VBIO): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 6, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 6, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Valion Bio (VBIO), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Valion Bio, Inc. (VBIO) is the company analyzed here. It employs 52 people and is led by Michael R. Cavanaugh. In Q3 FY2026 it reported revenue of $146,000 and net income of -$3M. The market values it at $1.16M.
What do the latest results show for Valion Bio (VBIO)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $146,000. Against analyst estimates the company has EPS beat 8 of the last 8 reports.
Quarterly income statement — 1 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $146,000 | -$3M | -$1.97 (diluted) |
What are the financial strengths and risks for Valion Bio (VBIO)?
Short answer · as of
The MoonshotScore pillars rate business quality as strengths. What is holding it back is balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -4.49 · Piotroski F 2. Trailing ratios: ROA -57.7% · current ratio 1.11.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -4.49 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How does Valion Bio compare with its peers?
Short answer
Valion Bio's score ranks 11th of 11 in the bounded comparison shown, against 10 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.07 Nov 19, 2026 | $540M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $9.28 Nov 19, 2026 | $545M | 68 5-pillar Nov 18, 2026 | |
| $3.13 Nov 19, 2026 | $481M | 60 5-pillar Nov 18, 2026 | |
| $6.78 Nov 19, 2026 | $541M | 60 5-pillar Nov 18, 2026 | |
| Valion Bio (VBIO) — this page | $0.5399 | $1.16M | 30 |
| $0.98 Nov 13, 2026 | $16.5M | — Model unavailable | |
| $0.01 Oct 2, 2026 | $19.6M | — Model unavailable |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 22, 2026
- Transactions
- 6
- Identified insiders
- 2
- Purchases
- 0
- Sales
- 0
- Other transactions
- 6
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held VBIO in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported VBIO in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Valion Bio (VBIO)?
- Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study
- Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird's National Security Conference
- Valion Bio President, COO And CFO Lisa Wolf To Resign, Effective December 11
Common Questions About VBIO
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for VBIO?
VBIO carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is VBIO a good stock to buy?
Stock Expert AI does not rate VBIO buy, sell or hold. Valion Bio, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the VBIO stock price today?
The last price recorded for Valion Bio, Inc. (VBIO), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for VBIO?
Valion Bio, Inc. (VBIO) holds a MoonshotScore in the low range. This could include conditions such as arthritis, multiple sclerosis, and Crohn's disease. Not financial advice.
How frequently does VBIO data refresh on this page?
VBIO's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven VBIO's recent stock price performance?
Valion Bio, Inc. (VBIO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VBIO overvalued or undervalued right now?
Valion Bio, Inc. (VBIO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VBIO before investing?
Before investing in Valion Bio, Inc. (VBIO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding VBIO to a portfolio?
No dossier-level strength is on record for Valion Bio, Inc. (VBIO) yet — start from the MoonshotScore factor breakdown and the Financials tab on this page. Weigh rewards against risks and diversify. Not financial advice.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 17 figures on this page — 8 from Financial Modeling Prep (FMP), 7 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com